International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award
International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award supports investigators' translational research on plasma cell disorders to improve myeloma care.
Browse similar grants
Funder: International Myeloma Society
Due Dates: January 29, 2027, at 11:59 p.m. EST (Application deadline)
Funding Amounts: $175,000–$250,000 USD, including up to 8% institutional overhead; conditional second-year funding
Summary: Supports investigator-initiated translational research to improve prevention, early detection, diagnosis, and treatment of plasma cell disorders.
Key Information: The PI or Co-I should be an IMS member; previous awardees cannot apply with a different proposal.
Description
The International Myeloma Society (IMS) and Paula and Rodger Riney Foundation support investigator-initiated translational research in plasma cell dyscrasias, with a focus on finding a cure for multiple myeloma. The program aims to improve prevention, early detection, diagnosis, and treatment while encouraging collaboration between institutions.
Eligible research spans molecular assays, imaging techniques, drugs, biological agents, and other methodologies applicable to myeloma treatment. Projects may use cellular, molecular, structural, biochemical, or genetic approaches. Research may move toward clinical trials, prevention, early detection, treatment, and biomarkers, or work in reverse using human biospecimens to investigate phenomena, identify targets, and develop treatments. Projects must result in clinical translation and have the potential to change the current paradigm in myeloma management.
